Trials / Completed
CompletedNCT00090519
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 731 (actual)
- Sponsor
- Chromaderm, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ruboxistaurin | 32 mg once daily (QD) oral for up to 36 months |
| DRUG | placebo | QD oral for up to 36 months |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2004-08-31
- Last updated
- 2016-10-06
- Results posted
- 2016-05-16
Locations
84 sites across 17 countries: United States, Australia, Brazil, Canada, Denmark, France, Germany, India, Italy, Mexico, Netherlands, Poland, Portugal, Russia, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00090519. Inclusion in this directory is not an endorsement.